Halozyme (HALO) | Stock Overview & Key Data

Halozyme Therapeutics Inc. | Mid-cap | Healthcare

$52.02

-0.36%

| Halozyme Stock Comparison:

Halozyme vs Vertex Halozyme vs Regeneron Halozyme vs Blueprint Medicines Halozyme vs Roivant Sciences Halozyme vs Bio-Techne Halozyme vs S&P 500 | Market

Chart Range Statistics Financials Returns Ownership Calculator FAQ

Halozyme Performance Comparison

Loading chart data...

Halozyme

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: $51.06 High: $53.44

on June 30, 2025

52 Week Range

Low: $42.01 High: $70.51

on November 18, 2024

on May 7, 2025

All-Time High: $70.51 on May 5, 2025

Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights

Key Statistics

Market Cap i $6.5B

EPS i 3.76

P/E Ratio (TTM) i 14.04

Forward P/E i 10.91

P/B Ratio i 13.49

PEG Ratio i 10.91

Div. Yield i N/A

ROE i 147.06%

Beta i 1.185

Debt to Equity i 318.67

Financial Highlights

Profitability

Gross Margin i 81.73%

Operating Margin i 53.44%

Profit Margin i 44.76%

Returns and Earnings

Return on Assets (TTM) i 18.50%

Return on Equity (TTM) i 147.06%

EBITDA i $679.0M

Net Income (TTM) i $485.4M

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i

Quarterly Earnings Growth i

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Halozyme HALO	6.51B Mid-cap	-1.48%	-7.22%	-18.48%	8.40%	8.35%	0.89%	0.46%	86.45%
Vertex VRTX	114.06B Large-cap	0.37%	0.71%	-8.17%	11.48%	9.72%	-5.40%	54.32%	52.32%
Regeneron REGN	55.27B Large-cap	2.56%	7.08%	-17.22%	-25.28%	-26.59%	-49.24%	-15.54%	-15.44%
Blueprint Medicines BPMC	8.29B Mid-cap	-0.17%	26.47%	44.82%	47.64%	47.00%	14.75%	126.55%	62.31%
Roivant Sciences ROIV	7.82B Mid-cap	-2.00%	2.55%	11.69%	-1.40%	-6.71%	5.82%	132.85%	13.61%
Bio-Techne TECH	7.92B Mid-cap	4.36%	6.30%	-12.25%	-28.83%	-28.02%	-26.31%	-40.20%	-21.53%

Ownership & Short Interest

Insider Ownership i 1.18%

Institutional Ownership i 102.10%

Shares Short i 11M

Short Ratio i 3.21

Short % of Shares Outstanding i 11.72%

Average 10-Day Volume i 2M

Average 90-Day Volume i 3M

Halozyme Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Halozyme would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is HALO's 52-week high and low?

In the last 52 weeks, Halozyme reached a high of $70.51 (on May 7, 2025) and a low of $42.01 (on November 18, 2024).

What is the market cap and P/E ratio for HALO?

Curious about Halozyme's size and valuation? Its market capitalization stands at 6.51B. When it comes to valuation, the P/E ratio (trailing twelve months) is 14.04, and the forward P/E (looking ahead) is 10.91.

Does HALO pay dividends? If so, what's the yield?

As for dividends, Halozyme isn't currently offering a significant yield, or that specific data isn't available right now.

Who are Halozyme's main competitors or similar companies to consider before investing?

When looking at Halozyme, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Vertex VRTX	114.06B	Healthcare	Biotechnology	-5.40%	54.32%
Regeneron REGN	55.27B	Healthcare	Biotechnology	-49.24%	-15.54%
Blueprint Medicines BPMC	8.29B	Healthcare	Biotechnology	14.75%	126.55%
Roivant Sciences ROIV	7.82B	Healthcare	Biotechnology	5.82%	132.85%
Bio-Techne TECH	7.92B	Healthcare	Biotechnology	-26.31%	-40.20%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Halozyme Therapeutics Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Halozyme's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 147.06%, the Debt to Equity ratio from the most recent quarter is 318.67, and its Gross Profit Margin stands at 81.73%.

What is the recent revenue and earnings growth for HALO?

Looking at Halozyme's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 35.20%, and quarterly earnings saw a YoY growth of 53.70%.

How much of HALO stock is held by insiders and institutions?

Wondering who owns Halozyme stock? Company insiders (like executives and directors) hold about 1.18% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 102.10%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.